Sustained Health-Related Quality of Life (HRQoL) Improvement in Newly Diagnosed Multiple Myeloma Patients Treated with Bortezomib/Melphalan/Prednisone Versus Melphalan/Prednisone: Results From the VISTA Trial.

被引：0

作者：

Dhawan, Ravinder ^{[1
]}

Robinson, Don, Jr. ^{[1
]}

Meunier, Juliette ^{[2
]}

Regnault, Antoine ^{[2
]}

Rosa, Kathleen ^{[3
]}

Cakana, Andrew Z. ^{[4
]}

van de Velde, Helgi ^{[5
]}

Richardson, Paul G. ^{[6
]}

San Miguel, Jesus F. ^{[7
]}

机构：

[1] Johnson & Johnson Pharmaceut Res & Dev, Raritan, NJ USA

[2] Mapi Values, Lyon, France

[3] Mapi Values, Boston, MA USA

[4] Johnson & Johnson Pharmaceut Res & Dev, High Wycombe, Bucks, England

[5] Johnson & Johnson Pharmaceut Res & Dev, Bonaire, Neth Antilles

[6] Dana Farber Canc Inst, Boston, MA 02115 USA

[7] Hosp Univ Salamanca, Hematol Serv, Salamanca, Spain

来源：

BLOOD | 2009年 / 114卷 / 22期

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：747 / 747

页数：1

共 50 条

[31] DARATUMUMAB PLUS BORTEZOMIB, MELPHALAN, AND PREDNISONE (D-VMP) VERSUS BORTEZOMIB, MELPHALAN, AND PREDNISONE (VMP) IN NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM) PATIENTS (PTS) INELIGIBLE FOR TRANSPLANT: A PHASE 3 RANDOMIZED STUDY (ALCYONE)
Mateos, M., V
Dimopoulos, M. A.
Cavo, M.
Suzuki, K.
Jakubowiak, A.
Knop, S.
Doyen, C.
Lucio, P.
Nagy, Z.
Kaplan, P.
Pou
Cook, M.
Grosicki, S.
Crepaldi, A.
Liberati, A. M.
Campbell, P.
Shelekhova, T.
Yoon, S. S.
Iosava, G.
Fujisaki, T.
Garg, M.
Chiu, C.
Wang, J.
Carson, R.
Crist, W.
Deraedt, W.
Nguyen, H.
Qi, M.
San-Miguel, J.
HAEMATOLOGICA, 2018, 103 : 22 - 22
[32] Phase 3 Randomized Study of Daratumumab Plus Bortezomib, Melphalan, and Prednisone (D-VMP) Versus Bortezomib, Melphalan, and Prednisone (VMP) in Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts) Ineligible for Transplant (ALCYONE)
Mateos, Maria-Victoria
Dimopoulos, Meletios A.
Cavo, Michele
Suzuki, Kenshi
Jakubowiak, Andrzej J.
Knop, Stefan
Doyen, Chantal
Lucio, Paulo
Nagy, Zsolt
Kaplan, Polina
Pour, Ludek
Cook, Mark
Grosicki, Sebastian
Crepaldi, Andre H.
Liberati, Anna Marina
Campbell, Philip
Shelekhova, Tatiana
Yoon, Sung-Soo
Iosava, Genadi
Fujisaki, Tomoaki
Garg, Mamta
Chiu, Christopher
Wang, Jianping
Carson, Robin
Crist, Wendy
Deraedt, William
Nguyen, Marie
Qi, Ming
San-Miguel, Jesus F.
BLOOD, 2017, 130
[33] Lenalidomide, melphalan, and prednisone, followed by lenalidomide maintenance, improves health-related quality of life in newly diagnosed multiple myeloma patients aged 65 years or older: results of a randomized phase III trial
Dimopoulos, Meletios A.
Delforge, Michel
Hajek, Roman
Kropff, Martin
Petrucci, Maria T.
Lewis, Philip
Nixon, Annabel
Zhang, Jingshan
Mei, Jay
Palumbo, Antonio
HAEMATOLOGICA, 2013, 98 (05) : 784 - 788
[34] Bortezomib-Melphalan-Prednisone (VMP) in Newly Diagnosed Multiple Myeloma Patients with Impaired Renal Function: Cohort Analysis of the Phase III VISTA Study
Dimopoulos, Meletios A.
Richardson, Paul
Schlag, Rudolf
Khuageva, Nuriet K.
Shpilberg, Ofer
Kastritis, Efstathios
Kropff, Martin H.
Petrucci, Maria Teresa
Delforge, Michel
Alexeeva, Julia A.
Schots, Rik
Masszi, Tamas
Mateos, Maria-Victoria
Deraedt, William
Liu, Kevin
Cakana, Andrew
van de Velde, Helgi
Miguel, Jesus F. San
BLOOD, 2008, 112 (11) : 608 - 609
[35] E1A06: A phase III trial comparing melphalan, prednisone, and thalidomide (MPT) versus melphalan, prednisone, and lenalidomide (MPR) in newly diagnosed multiple myeloma (MM).
Stewart, A. Keith
Jacobus, Susanna J.
Fonseca, Rafael
Weiss, Matthias
Callander, Natalie Scott
Chanan-Khan, Asher Alban Akmal
Rajkumar, Vincent
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
[36] E1A06: A PHASE III TRIAL COMPARING MELPHALAN, PREDNISONE, AND THALIDOMIDE (MPT) VERSUS MELPHALAN, PREDNISONE, AND LENALIDOMIDE (MPR) IN NEWLY DIAGNOSED MULTIPLE MYELOMA MM)
Stewart, A. K.
Jacobus, S.
Fonseca, R.
Weiss, M.
Callander, N. S.
Chanan-Khan, A. A.
Rajkumar, S. V.
HAEMATOLOGICA, 2014, 99 : 220 - 220
[37] Daratumumab, Bortezomib, Melphalan, and Prednisone (D-VMP) Versus Bortezomib, Melphalan, and Prednisone (VMP) Alone in Transplant-Ineligible Asian Patients with Newly Diagnosed Multiple Myeloma: Final Analysis of the Phase 3 Octans Study
Fu, Weijun
Bang, Soo-Mee
Huang, Honghui
Kim, Kihyun
Li, Wei
An, Gang
Lee, Je-Jung
Cai, Zhen
Jin, Jie
Wang, Yafei
Chim, Chor Sang
Carson, Robin
Liu, Rui
Wang, Lingling
Zhao, Man
Chen, Xi
Cui, Canchan
Hou, Jian
Wang, Jianxiang
BLOOD, 2023, 142
[38] Combination of bortezomib, melphalan, prednisone and thalidomide (VMPT) for relapsed multiple myeloma: Results of a phase I/II clinical trial.
Palumbo, Antonio
Ambrosini, Maria Teresa
Benevolo, Giulia
Pregno, Patrizia
Pescosta, Norbert
Callea, Vincenzo
Cangialosi, Clotilde
Caravita, Tommaso
Morabito, Fortunato
Musto, Legrino
Bringhen, Sara
Gay, Francesca
Rus, Cecilia
Boccadoro, Mario
BLOOD, 2006, 108 (11) : 125A - 125A
[39] Health-related quality of life (HRQOL) in transplant-ineligible patients (pts) with newly diagnosed multiple myeloma (NDMM): Results from the first trial.
Delforge, Michel
Minuk, Leonard
Eisenmann, Jean-Claude
Arnulf, Bertrand
Canepa, Letizia
Fragasso, Alberto
Leyvraz, Serge
Langer, Christian
Ezaydi, Yousef
Vogl, Dan T.
Giraldo-Castellano, Pilar
Yoon, Sung-Soo
Martins, Angelo
Zarnitsky, Charles
Barbe, Martine Escoffre
Lemieux, Bernard
Proskorovsky, Irina
Ervin-Haynes, Annette L.
Houck, Vanessa
Facon, Thierry
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
[40] Bortezomib-Melphalan-Prednisone (VMP) Versus MP As Initial Treatment for Patients Older Than 75 Years with Newly Diagnosed Multiple Myeloma
Kim, Min Kyoung
Kim, Kihyun
Yoon, Dok Hyun
Suh, Cheolwon
Lee, Jae Hoon
Jung, Sung-Hoon
Lee, Je-Jung
Kim, Hyo Jung
Kim, Jin Seok
Lee, Jeong-Ok
Eom, Hyeon Seok
Lee, Won Sik
Mun, Yeung-Chul
Do, Young Rok
Kang, Hye Jin
BLOOD, 2016, 128 (22)

← 1 2 3 4 5 →